Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
arthritis
Biotech
UCB's bispecific notches phase 3 win for spinal arthritis
After beating out Johnson & Johnson's Stelara in psoriasis in 2020, UCB's bispecific inhibitor has wracked up another phase 3 win.
Kyle LaHucik
Jan 18, 2022 10:21am
Acelyrin snags $250M, licenses Affibody IL-17 asset for 3 trials
Nov 16, 2021 5:00am
Novartis adds AI-based diagnostic surveys to online disease hubs
May 13, 2021 3:40pm
Novartis’ Ilaris cuts rate of joint replacements from arthritis
Aug 3, 2020 5:00pm
Gilead builds case for filgotinib in active psoriatic arthritis
Jun 8, 2020 8:10am
Dogs help Lilly scientists identify new osteoarthritis target
Nov 1, 2019 8:40am
